يعرض 161 - 180 نتائج من 18,253 نتيجة بحث عن '(( significant impact decrease ) OR ( significant ((a decrease) OR (nn decrease)) ))', وقت الاستعلام: 0.56s تنقيح النتائج
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169

    Seven forecast scenarios. حسب Ryan P. Thombs (9138968)

    منشور في 2025
    الموضوعات:
  10. 170

    Forecast for each scenario, 2023-2032. حسب Ryan P. Thombs (9138968)

    منشور في 2025
    الموضوعات:
  11. 171

    Coefficient plot of short-run effects. حسب Ryan P. Thombs (9138968)

    منشور في 2025
    الموضوعات:
  12. 172

    Coefficient plot of long-run effects. حسب Ryan P. Thombs (9138968)

    منشور في 2025
    الموضوعات:
  13. 173
  14. 174

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…"
  15. 175

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…"
  16. 176

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…</p>Methods<p>In vitro cell suppression, phenotype change, IL-10 secretion, and cytokine levels in coculture supernatants were determined to quantify the impact of adding ruxolitinib to UCB-Tregs. A xenogeneic SLE model was utilized to study their in vivo combination.…"
  17. 177
  18. 178
  19. 179
  20. 180